Review
Pharmacology & Pharmacy
Yu Jiao, Dongjuan Liu, Yi Sun, Zitong Chen, Sai Liu
Summary: The study found that metformin treatment can improve the overall survival of head and neck cancer patients, especially in studies with higher scores. Age and comorbidities also influence the therapeutic effect of metformin.
FRONTIERS IN PHARMACOLOGY
(2022)
Review
Oncology
Yifan Lu, Ali Hajjar, Vincent L. Cryns, Amy Trentham-Dietz, Ronald E. Gangnon, Brandy M. Heckman-Stoddard, Oguzhan Alagoz
Summary: This study suggests that women with type 2 diabetes are more likely to be diagnosed with breast cancer, and this association is strengthened when adjusting for BMI and menopausal status. There was no significant reduction in breast cancer risk among users of metformin.
Article
Medicine, General & Internal
Mingchuan Guo, Xiaofei Shang, Duanying Guo
Summary: This study found an association between metformin use and reduced mortality in women with ovarian cancer through a meta-analysis. This association may be independent of the control group's diabetic status, timing of metformin use, body mass index, and concurrent medications. Clinical trials are needed to validate the potential benefits of metformin on the survival of ovarian cancer.
INTERNATIONAL JOURNAL OF CLINICAL PRACTICE
(2022)
Review
Endocrinology & Metabolism
Hua Fan, Shikun Bai, Xin Guan, Wen Ma, Yu Fu, Xuan Zhang, Lili Deng, Jing Tian
Summary: A systematic literature search found that patients with concurrent SCLC and DM using metformin had significantly longer overall survival (OS) and disease-free survival (DFS) compared to those without metformin usage.
MINERVA ENDOCRINOLOGY
(2023)
Review
Medicine, General & Internal
Jing Yang, Hang Yang, Ling Cao, Yuzhen Yin, Ying Shen, Wei Zhu
Summary: Metformin has potential benefits for the survival and progression-free survival of cancer patients, especially in breast cancer, and also showed potential benefits in cancer-specific survival in colorectal and prostate cancer.
Review
Pharmacology & Pharmacy
Xiaofeng Luo, Xi Chen, Lin Wang, Bowen Yang, Shuang Cai
Summary: The combination of metformin and antineoplastic agents showed significant improvement in overall survival and progression-free survival outcomes in lung cancer patients, especially in non-diabetic patients. However, further investigation is needed to confirm these findings, as limited data from randomized controlled trials showed no differences in survival outcomes.
FRONTIERS IN PHARMACOLOGY
(2021)
Article
Oncology
Anthony M. Joshua, Andrew Armstrong, Megan Crumbaker, Howard Scher, Johann de Bono, Bertrand Tombal, Maha Hussain, Cora N. Sternberg, Silke Gillessen, Joan Carles, Karim Fizazi, Ping Lin, William Duggan, Jennifer Sugg, David Russell, Tomasz M. Beer
Summary: This study analyzed the impact of statins and metformin on treatment outcomes in patients with castration-resistant prostate cancer. The results showed inconsistent associations between the use of statins and metformin and radiographic progression-free survival (rPFS), metastasis-free survival (MFS), and overall survival (OS) across different trials. The pooled analysis revealed that statin use was significantly associated with a reduced risk of death in enzalutamide-treated patients, while metformin use was not significant.
EUROPEAN JOURNAL OF CANCER
(2022)
Article
Multidisciplinary Sciences
Tianli Hui, Chao Shang, Liu Yang, Meiqi Wang, Ruoyang Li, Zhenchuan Song
Summary: Early reports suggest that the drug metformin, used to treat T2DM, may have a positive impact on the prognosis of cancer. A study on Chinese breast cancer patients with T2DM found that those using metformin showed improved disease-free and overall survival compared to those not using the drug.
SCIENTIFIC REPORTS
(2021)
Review
Pharmacology & Pharmacy
Xinyan Gan, Chang Cao, Yan He, Xiaolin Hu, Xingchen Peng, Yonglin Su
Summary: Meta-analysis showed that metformin does not significantly improve the survival of patients with advanced or unresectable cancer, and there is no clear evidence of increased toxicity.
CURRENT PHARMACEUTICAL DESIGN
(2022)
Review
Oncology
Kang Yang, Hao-hao Lu, Wei Zhao, Qingchun Zhao
Summary: A meta-analysis suggests that the use of metformin in cancer patients may prolong disease survival. However, further studies are needed to determine the efficacy of adjuvant chemotherapy with metformin in cancer patients without diabetes.
FRONTIERS IN ONCOLOGY
(2023)
Letter
Gastroenterology & Hepatology
Jan Dimberg, Levar Shamoun, Kalle Landerholm, Dick Wagsaeter
Summary: The association between type 2 diabetes mellitus (DM) and colorectal cancer (CRC) has been investigated, with reports suggesting an increased risk of CRC in DM patients. Metformin, with its anti-inflammatory effects, may protect against the development of CRC in DM patients and improve prognosis. However, in this cohort study, there were no associations between the presence of DM or metformin and cancer specific survival, plasma levels of inflammatory factors or irisin. A specific single nucleotide polymorphism in the insulin-like growth factor binding protein 7 gene was associated with DM in CRC patients.
WORLD JOURNAL OF GASTROENTEROLOGY
(2022)
Article
Multidisciplinary Sciences
Guocan Yu, Wenfeng Yu, Xudong Xu, Bo Ye, Liwei Yao
Summary: This study aims to evaluate the efficacy and safety of immunotherapy for resectable esophageal cancer as neoadjuvant treatment, providing reliable evidence for clinicians and patients to formulate the best pre-surgical treatment plan.
Article
Oncology
Sara Pusceddu, Claudio Vernieri, Massimo Di Maio, Natalie Prinzi, Martina Torchio, Francesca Corti, Jorgelina Coppa, Roberto Buzzoni, Maria Di Bartolomeo, Massimo Milione, Benjamin Regnault, Xuan-Mai Truong Thanh, Vincenzo Mazzaferro, Filippo de Braud
Summary: Lanreotide is effective in preventing tumor worsening in patients with neuroendocrine tumors of the intestines and pancreas, regardless of diabetic status. Metformin may also have potential antitumor effects.
Review
Oncology
Maria Teresa Climent, Anna Serra, Maria Llueca, Antoni Llueca
Summary: Ovarian cancer has a high mortality rate due to advanced diagnosis and high recurrence rate. Systemic chemotherapy is the standard treatment for recurrent ovarian cancer, but secondary cytoreductive surgery may also be effective. This study analyzed multiple randomized controlled trials and found significant improvements in overall survival and disease-free survival for patients who underwent complete secondary cytoreductive surgery.
Article
Endocrinology & Metabolism
Lingna Li, Jianing Huang, Tongmin Huang, Jie Yao, Yeyuan Zhang, Meiling Chen, Haojie Shentu, Haiying Lou
Summary: Based on a comprehensive analysis of relevant studies, this study found that the use of metformin treatment may have a positive effect on the prognosis of gastric cancer patients with type 2 diabetes mellitus, prolonging overall survival, cancer-specific survival, and progression-free survival.
INTERNATIONAL JOURNAL OF ENDOCRINOLOGY
(2023)
